Product
INTELENCE™ (etravirine)
Supplier Directory - Disclaimer and Copyright
 |
Tibotec Therapeutics Division of Centocor Ortho Biotech Products, L.P. (Johnson & Johnson)
INTELENCE™ (etravirine) 100 mg tablets are a non-nucleoside reverse transcriptase inhibitor (NNRTI) approved by the U.S. Food and Drug Administration (FDA) in January 2008. Intelence is approved for treatment-experienced patients who have HIV strains that are resistant to an NNRTI and other HIV drugs. Intelence works by blocking HIV's reverse transcriptase enzyme.
Changes to the INTELENCES™ (etravirine) 100 mg tablets manufacturing process have made significant environmental impacts. There has been a 60% reduction in the use of methylene chloride in spray drying step via recycling back into the process, and a reduction of the spent waste solvents; 540,000 liters/yr spent solvent elimination. The yield has also been increased.
Johnson & Johnson
